Benefits of Melatonin

Evidence-Based Benefits

• Sleep onset — a 2013 meta-analysis of 19 RCTs (Ferracioli-Oda et al.) found melatonin supplementation significantly reduced sleep onset latency by a weighted mean of 7.06 minutes compared to placebo, with improvements in total sleep time and sleep quality
• Sleep quality — melatonin improved subjective sleep quality scores across studies, with benefits most pronounced in primary sleep disorders and delayed sleep-wake phase disorder
• Jet lag treatment — a 2002 Cochrane systematic review (Herxheimer & Petrie) of 10 trials found melatonin remarkably effective for preventing or reducing jet lag, particularly when crossing 5 or more time zones and traveling eastward
• Circadian rhythm resetting — melatonin acts as a chronobiotic, shifting the phase of the circadian clock, making it the treatment of choice for delayed sleep-wake phase disorder and shift work sleep difficulties
• Antioxidant effects — melatonin is a potent direct free radical scavenger and also stimulates antioxidant enzymes (superoxide dismutase, glutathione peroxidase), providing neuroprotective effects beyond sleep

What the Research Says

Melatonin is one of the most extensively studied sleep supplements. Ferracioli-Oda et al. (2013) conducted a meta-analysis of 19 randomized controlled trials (RCTs) involving 1,683 subjects, demonstrating that melatonin significantly reduces sleep onset latency by -7.06 minutes on average, increases total sleep time by +8.25 minutes, and improves overall sleep quality. Herxheimer & Petrie (2002) confirmed melatonin's efficacy for jet lag prevention and treatment through a Cochrane review of 10 trials. Brzezinski et al. (2005) meta-analyzed 17 studies, confirming melatonin's sleep-promoting effects and noting that its efficacy does not diminish with continued use over weeks.

A key finding across the literature is the absence of a clear dose-response relationship. Zhdanova et al. (2001) demonstrated that physiological doses (0.3mg) were as effective as pharmacological doses (3mg) for improving sleep in older adults with insomnia. Recent studies have expanded on melatonin's applications, including its use in critically ill patients. Tang et al. (2025) found that melatonin may reduce delirium, slightly shorten ICU stay, and improve sleep quality in this population, though evidence is of low certainty.

In heart failure patients, Daliri et al. (2025) reported that melatonin improves quality of life (p=0.001), though it has no significant effect on ejection fraction (p=0.27). Additionally, Cruz-Sanabria et al. (2024) systematically reviewed 26 RCTs to optimize the timing and dosage of melatonin as a sleep-promoting drug, further supporting its efficacy across diverse populations.

Related Conditions